Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monalizumab + ibrutinib
- Development stage
- Discontinued
- Lead developer
- Innate Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (for Monalizumab), Oral (for Ibrutinib)
01
Overview
The combination of **monalizumab** (a monoclonal antibody targeting NKG2A) and **ibrutinib** (a small molecule inhibitor of Bruton tyrosine kinase, BTK) is an investigational therapy evaluated primarily for the treatment of chronic lymphocytic leukemia (CLL). Monalizumab acts as an immune checkpoint inhibitor by blocking the inhibitory receptor NKG2A on immune cells, potentially enhancing natural killer (NK) cell and CD8+ T cell anti-tumor activity. Ibrutinib is a covalent BTK inhibitor, disrupting B cell receptor signaling essential to CLL cell survival and proliferation. The rationale for their combination is to simultaneously inhibit CLL cell survival/proliferation (by ibrutinib) and boost anti-tumor immunity (by monalizumab), with the aim of increasing rates of complete response and MRD negativity compared to either agent alone. The primary indication investigated is relapsed, refractory, or previously untreated CLL. Monalizumab was developed by Innate Pharma, and ibrutinib by Pharmacyclics and Janssen.
- Brand names
- Imbruvica (for ibrutinib)
- Other names
- monalizumab and ibrutinib
02
Targets
BTK (Bruton tyrosine kinase)KLRC1 (Killer cell lectin-like receptor subfamily C member 1)
Beyond the preview
Go deeper on monalizumab + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monalizumab + ibrutinib.